Hepatology| 肝癌患者肝移植术后结果:美国多中心队列报告

2021-01-03 MedSci原创 MedSci原创

在肝移植患者中,通过等待时间、AFP对局部治疗的反应和肿瘤负担可以导致肝移植的优良结局,证明肝移植米兰标准的扩展是合理的。

近日,2020年全球最新癌症负担报告由世界卫生组织下属国际癌症研究机构(IARC)发布,报告对2020年度全球常见的癌症类型、导致死亡主要癌症类型以及未来的癌症发展趋势进行了全面的分析。数据显示,2020年新发各类癌症共计1930万例,死亡近1000万例。几乎每5人中就有1人在一生中会罹患癌症,而每8名男性、每11名女性中即有1人因癌症而死亡。

而作为肝癌大国,肝癌仍是我国第6大最常见的恶性肿瘤之一。癌症致死的患者位列我国第3位。

2020年全球最常见癌症死亡及占比. https://www.iarc.fr/faq/latest-global-cancer-data-2020-qa/

肝移植是治疗各种类型肝衰竭、一些非肝功能衰竭和肝癌(HCC)的一种非常成功的方法。它不但祛除了肿瘤而且还能治愈引起复发的基础疾病。但由于器官来源的限制、等待过程中肿瘤的进展、高额的移植费用而受到较大局限。

肝移植术一直是符合条件的不可切除的HCC患者的治疗金标准。米兰标准是目前国际上应用最为广泛的肝癌肝移植受体筛选标准。具体是指单个肿瘤直径不超过5cm或较多发的肿瘤少于3个并且最大直径不超过3cm,没有大血管侵犯现象,也没有淋巴结或外转移的征象。

有研究报道,根据米兰标准的HCC患者的5年后肝移植生存率为75-80%,HCC复发率为10-15%。然而,随着美国HCC发病率和死亡率的上升,对肝移植的需求也在增加。同时,美国器官采购和移植网络最近批准了肝脏移植的优先级,用于超过米兰标准的HCC患者,这些患者通过局部定位治疗进行降级。

为此,来自美国UCLA的专家团队对美国多中心HCC移植联盟(20个中心,2002-2013年)中超越米兰标准的HCC患者的肝移植后结果、降级的预测因素以及局部治疗的影响进行了评估。结果发表在肝脏病学权威杂志Hepatology上。

研究人员比较了符合米兰标准(n=3570)和米兰标准外(n=789)患者的临床病理特征、总生存期(OS)、无复发生存期(RFS)和HCC复发(HCC-R)的情况。其中米兰标准外的患者被进一步分为降级(DS,n=465)、接受定位治疗但未降级(LRT-NODS,n=242)或未治疗(NOLRT-NODS,n=82)。

结果显示,与DS(64.3%和59.5%)相比,米兰标准(71.3%和68.2%)的5年移植后OS和RFS更高,而NODS(n=324;60.2%和53.8%)相对最低。与NODS相比,DS患者的RFS更优(60% vs 54%),5年HCC-R更低(18% vs 32%)。进一步按最大放射肿瘤直径分层(DS/<5cm的5年HCC-R为15.5%,NoDS/>5cm的为39.1%)。

其中,降级治疗的多变量预测因素包括AFP对局部治疗的反应,肿瘤的数量和大小以及治疗等待时间>12个月。与NoLRT-NoDS相比,即使在控制了临床病理变量(HR=2.33)和治疗加权倾向匹配的反概率(HR=1.82)之后,LRT-NoDS HCC-R率也更高(34.1% vs 26.1%)。

综上,在肝移植患者中,通过等待时间、AFP对局部治疗的反应和肿瘤负担可以导致肝移植的优良结局,证明肝移植米兰标准的扩展是合理的。

 

参考文献:

Kardashian A, et al. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients with Hepatocellular Carcinoma Presenting Beyond Milan Criteria. Hepatology. 2020 Mar 2. doi: 10.1002/hep.31210.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1999002, encodeId=b8c619990025a, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 31 10:59:32 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969039, encodeId=470a19690399a, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Tue Nov 23 13:59:32 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961963, encodeId=283896196365, content=<a href='/topic/show?id=f86610425849' target=_blank style='color:#2F92EE;'>#J Hepatology#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104258, encryptionId=f86610425849, topicName=J Hepatology)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:47:46 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904048, encodeId=c4f0190404863, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jul 02 08:59:32 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427478, encodeId=02c5142e4788d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jan 05 00:59:32 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913724, encodeId=4674913e2469, content=香积寺死的快, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201107/0e992c9cbb7e4bfc82d642ba0e9fe718/6fa4c63468cc49febcc91dba2fb4201a.jpg, createdBy=fa625399541, createdName=DIfh, createdTime=Mon Jan 04 21:53:45 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040334, encodeId=08fb104033437, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jan 03 12:59:32 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
    2021-10-31 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=1999002, encodeId=b8c619990025a, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 31 10:59:32 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969039, encodeId=470a19690399a, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Tue Nov 23 13:59:32 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961963, encodeId=283896196365, content=<a href='/topic/show?id=f86610425849' target=_blank style='color:#2F92EE;'>#J Hepatology#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104258, encryptionId=f86610425849, topicName=J Hepatology)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:47:46 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904048, encodeId=c4f0190404863, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jul 02 08:59:32 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427478, encodeId=02c5142e4788d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jan 05 00:59:32 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913724, encodeId=4674913e2469, content=香积寺死的快, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201107/0e992c9cbb7e4bfc82d642ba0e9fe718/6fa4c63468cc49febcc91dba2fb4201a.jpg, createdBy=fa625399541, createdName=DIfh, createdTime=Mon Jan 04 21:53:45 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040334, encodeId=08fb104033437, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jan 03 12:59:32 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1999002, encodeId=b8c619990025a, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 31 10:59:32 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969039, encodeId=470a19690399a, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Tue Nov 23 13:59:32 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961963, encodeId=283896196365, content=<a href='/topic/show?id=f86610425849' target=_blank style='color:#2F92EE;'>#J Hepatology#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104258, encryptionId=f86610425849, topicName=J Hepatology)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:47:46 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904048, encodeId=c4f0190404863, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jul 02 08:59:32 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427478, encodeId=02c5142e4788d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jan 05 00:59:32 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913724, encodeId=4674913e2469, content=香积寺死的快, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201107/0e992c9cbb7e4bfc82d642ba0e9fe718/6fa4c63468cc49febcc91dba2fb4201a.jpg, createdBy=fa625399541, createdName=DIfh, createdTime=Mon Jan 04 21:53:45 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040334, encodeId=08fb104033437, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jan 03 12:59:32 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
    2021-04-30 MedSciZeng

    #J Hepatology#点击进入话题查看更多相关文章 或评论时插入话题加入讨论

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1999002, encodeId=b8c619990025a, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 31 10:59:32 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969039, encodeId=470a19690399a, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Tue Nov 23 13:59:32 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961963, encodeId=283896196365, content=<a href='/topic/show?id=f86610425849' target=_blank style='color:#2F92EE;'>#J Hepatology#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104258, encryptionId=f86610425849, topicName=J Hepatology)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:47:46 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904048, encodeId=c4f0190404863, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jul 02 08:59:32 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427478, encodeId=02c5142e4788d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jan 05 00:59:32 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913724, encodeId=4674913e2469, content=香积寺死的快, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201107/0e992c9cbb7e4bfc82d642ba0e9fe718/6fa4c63468cc49febcc91dba2fb4201a.jpg, createdBy=fa625399541, createdName=DIfh, createdTime=Mon Jan 04 21:53:45 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040334, encodeId=08fb104033437, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jan 03 12:59:32 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1999002, encodeId=b8c619990025a, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 31 10:59:32 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969039, encodeId=470a19690399a, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Tue Nov 23 13:59:32 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961963, encodeId=283896196365, content=<a href='/topic/show?id=f86610425849' target=_blank style='color:#2F92EE;'>#J Hepatology#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104258, encryptionId=f86610425849, topicName=J Hepatology)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:47:46 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904048, encodeId=c4f0190404863, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jul 02 08:59:32 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427478, encodeId=02c5142e4788d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jan 05 00:59:32 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913724, encodeId=4674913e2469, content=香积寺死的快, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201107/0e992c9cbb7e4bfc82d642ba0e9fe718/6fa4c63468cc49febcc91dba2fb4201a.jpg, createdBy=fa625399541, createdName=DIfh, createdTime=Mon Jan 04 21:53:45 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040334, encodeId=08fb104033437, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jan 03 12:59:32 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
    2021-01-05 gwc384
  6. [GetPortalCommentsPageByObjectIdResponse(id=1999002, encodeId=b8c619990025a, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 31 10:59:32 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969039, encodeId=470a19690399a, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Tue Nov 23 13:59:32 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961963, encodeId=283896196365, content=<a href='/topic/show?id=f86610425849' target=_blank style='color:#2F92EE;'>#J Hepatology#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104258, encryptionId=f86610425849, topicName=J Hepatology)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:47:46 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904048, encodeId=c4f0190404863, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jul 02 08:59:32 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427478, encodeId=02c5142e4788d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jan 05 00:59:32 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913724, encodeId=4674913e2469, content=香积寺死的快, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201107/0e992c9cbb7e4bfc82d642ba0e9fe718/6fa4c63468cc49febcc91dba2fb4201a.jpg, createdBy=fa625399541, createdName=DIfh, createdTime=Mon Jan 04 21:53:45 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040334, encodeId=08fb104033437, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jan 03 12:59:32 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
    2021-01-04 DIfh

    香积寺死的快

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1999002, encodeId=b8c619990025a, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Oct 31 10:59:32 CST 2021, time=2021-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969039, encodeId=470a19690399a, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Tue Nov 23 13:59:32 CST 2021, time=2021-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=961963, encodeId=283896196365, content=<a href='/topic/show?id=f86610425849' target=_blank style='color:#2F92EE;'>#J Hepatology#</a>点击进入话题查看更多相关文章 或评论时插入话题加入讨论, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=104258, encryptionId=f86610425849, topicName=J Hepatology)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221103/2796e00c9b4549e3b313ed9e7accc68f/b52d6d98bbe04782b5a4e2dd1ee80be2.jpeg, createdBy=078e1614372, createdName=MedSciZeng, createdTime=Fri Apr 30 17:47:46 CST 2021, time=2021-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1904048, encodeId=c4f0190404863, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Fri Jul 02 08:59:32 CST 2021, time=2021-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427478, encodeId=02c5142e4788d, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jan 05 00:59:32 CST 2021, time=2021-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913724, encodeId=4674913e2469, content=香积寺死的快, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201107/0e992c9cbb7e4bfc82d642ba0e9fe718/6fa4c63468cc49febcc91dba2fb4201a.jpg, createdBy=fa625399541, createdName=DIfh, createdTime=Mon Jan 04 21:53:45 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040334, encodeId=08fb104033437, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Jan 03 12:59:32 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
    2021-01-03 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0